Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

6-Br-APB

From Wikipedia, the free encyclopedia
Chemical compound
This article is about the dopamine D1 receptor agonist. For the amphetamine derivative, see6-APB.
Pharmaceutical compound
6-Br-APB
Identifiers
  • 3-allyl-6-bromo-1-phenyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol
CAS Number
PubChemCID
ChemSpider
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC19H20BrNO2
Molar mass374.278 g·mol−1
3D model (JSmol)
  • c3ccccc3C2CN(CC=C)CCc(c1Br)c2cc(O)c1O
  • InChI=1S/C19H20BrNO2/c1-2-9-21-10-8-14-15(11-17(22)19(23)18(14)20)16(12-21)13-6-4-3-5-7-13/h2-7,11,16,22-23H,1,8-10,12H2/t16-/m1/s1 checkY
  • Key:KKZGFVAZUKHFAC-MRXNPFEDSA-N checkY
 ☒NcheckY (what is this?)  (verify)

6-Br-APB is a synthetic compound that acts as aselectiveD1agonist,[1] with the (R)-enantiomer being a potentfull agonist, while the (S) enantiomer retains its D1 selectivity but is a weakpartial agonist.[2] (R)-6-Br-APB and similar D1-selective full agonists likeSKF-81,297 andSKF-82,958 produce characteristicanorectic effects, stereotyped behaviour and self-administration in animals, with a similar but not identical profile to that of dopaminergicstimulants such asamphetamine.[3][4][5]

See also

[edit]

References

[edit]
  1. ^Neumeyer JL, et al. (December 1991). "(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship".Journal of Medicinal Chemistry.34 (12):3366–71.doi:10.1021/jm00116a004.PMID 1684995.
  2. ^Neumeyer JL, Kula NS, Baldessarini RJ, Baindur N (April 1992). "Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue".Journal of Medicinal Chemistry.35 (8):1466–71.doi:10.1021/jm00086a016.PMID 1533424.
  3. ^Rosenzweig-Lipson S, Hesterberg P, Bergman J (September 1994). "Observational studies of dopamine D1 and D2 agonists in squirrel monkeys".Psychopharmacology.116 (1):9–18.doi:10.1007/BF02244865.PMID 7862937.S2CID 24204026.
  4. ^Weed MR, Woolverton WL (December 1995). "The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys".The Journal of Pharmacology and Experimental Therapeutics.275 (3):1367–74.PMID 8531104.
  5. ^Barrett AC, Miller JR, Dohrmann JM, Caine SB (2004). "Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats".Neuropharmacology.47 (Suppl 1):256–73.doi:10.1016/j.neuropharm.2004.07.007.PMID 15464142.S2CID 2959198.
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
Stimulants
Amphetamines and
phenethylamines
Adrenergic agonists
Other
Cannabinoid
antagonists
GLP-1,GIP,and / or
glucagon agonists
DACRAs
5-HT2C
receptor agonists
Absorption inhibitors
Uncouplers
Others
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Stub icon

Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=6-Br-APB&oldid=1316585948"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp